NCT04413123 - Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 5, 2020

Primary Completion Date

December 20, 2025

Study Completion Date

June 20, 2026

Conditions

Papillary Renal Cell CarcinomaUnclassified Renal Cell CarcinomaTranslocation Renal Cell CarcinomaChromophobe Renal Cell CarcinomaCollecting Duct Renal Cell CarcinomaRenal Cell CarcinomaUnresectable Advanced Renal Cell CarcinomaMetastatic Ncc Renal Cell Carcinoma

Interventions

DRUG

Cabozantinib

Cabozantinib predetermined protocol dosage po daily

DRUG

Nivolumab

Nivolumab predetermined protocol dosage via IV every 3 weeks

DRUG

Ipilimumab

Ipilimumab predetermined protocol dosage via IV every 3 weeks

Trial Locations (4)

75390

UT Southwestern Medical, Dallas

02115

Beth Israel Deaconess Medical Center, Boston

Brigham & Woman's Hospital, Boston

Dana Farber Cancer Institute, Boston